Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Zinecard, Totect
Dexrazoxane is a cardioprotective agent used to reduce the incidence and severity of doxorubicin-induced cardiomyopathy. It belongs to the class of bisdioxopiperazines and acts as an iron chelator, preventing the formation of reactive oxygen species that contribute to heart damage. It is administered intravenously prior to doxorubicin treatment.
For reducing the incidence and severity of cardiomyopathy associated with doxorubicin treatment.
May increase the risk of secondary malignancies, especially myelodysplastic syndrome and acute myeloid leukemia, when used with doxorubicin in women with metastatic breast cancer.
Outcome:
Increased risk of myelosuppression
Mechanism:
Additive myelosuppressive effects
Outcome:
Increased risk of nephrotoxicity
Mechanism:
Unknown
Outcome:
Increased risk of bleeding
Mechanism:
Additive antiplatelet effects
Most likely new formulation: Liposomal dexrazoxane for improved efficacy and reduced toxicity (2026, 30% confidence)
Based on usage patterns and clinical trial data, there is a low likelihood (<5%) of dexrazoxane being withdrawn from the market in the next 5 years.
Cardioprotective Agent, Iron Chelator
Bisdioxopiperazine